| Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) (NCT00704717) | Merck Sharp & Dohme LLC | 2005-09-01 |
| Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) (NCT00724893) | Merck Sharp & Dohme LLC | 2005-08-01 |
| Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED) (NCT00279565) | Indivior Inc. | 2005-08-01 |
| Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) (NCT00237484) | Merck Sharp & Dohme LLC | 2005-07-18 |
| The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) (NCT00441584) | Merck Sharp & Dohme LLC | 2005-07-01 |
| Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) (NCT00723892) | Merck Sharp & Dohme LLC | 2005-07-01 |
| Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C (NCT00227149) | University of Wuerzburg | 2005-07-01 |
| Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED) (NCT00787371) | Merck Sharp & Dohme LLC | 2005-06-01 |
| A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6 (NCT02791256) | Hoffmann-La Roche | 2005-06-01 |
| PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED) (NCT00724620) | Schering-Plough | 2005-06-01 |
| Project BEST: Buprenorphine Entry Into Substance Abuse Treatment (NCT02583243) | Yale University | 2005-05-01 |
| A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1 (NCT00115908) | Human Genome Sciences Inc. | 2005-05-01 |
| Pirfenidone, an Antifibrotic and Antiinflammatory Drug (NCT02161952) | University of Guadalajara | 2005-05-01 |
| Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus (NCT02761629) | Hoffmann-La Roche | 2005-04-01 |
| Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) (NCT00724295) | Merck Sharp & Dohme LLC | 2005-04-01 |
| SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C (NCT00110799) | GlaxoSmithKline | 2005-04-01 |
| Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) (NCT00704522) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) (NCT00202839) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients (NCT00166296) | Germans Trias i Pujol Hospital | 2005-03-01 |
| Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212) (NCT00255008) | Merck Sharp & Dohme LLC | 2005-03-01 |
| Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED) (NCT00255034) | Merck Sharp & Dohme LLC | 2005-02-01 |
| Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1) (NCT00104052) | Merck Sharp & Dohme LLC | 2005-02-01 |
| Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) (NCT00709059) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) (NCT00265395) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C (NCT00216775) | Kyoto University | 2004-12-01 |
| Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247) (NCT00705107) | Merck Sharp & Dohme LLC | 2004-11-01 |
| A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection (NCT00157534) | BioWest Therapeutics Inc | 2004-10-01 |
| Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. (NCT00107653) | Hoffmann-La Roche | 2004-10-01 |
| Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) (NCT00727259) | Merck Sharp & Dohme LLC | 2004-10-01 |
| PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. (NCT00087633) | Hoffmann-La Roche | 2004-10-01 |
| Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206) (NCT00723879) | Merck Sharp & Dohme LLC | 2004-10-01 |
| Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis (NCT00148837) | French National Agency for Research on AIDS and Viral Hepatitis | 2004-09-01 |
| A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection (NCT00192647) | Hoffmann-La Roche | 2004-08-01 |
| A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients (NCT00088140) | Conatus Pharmaceuticals Inc. | 2004-07-01 |
| HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD) (NCT02806505) | Hoffmann-La Roche | 2004-06-01 |
| Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C (NCT00148863) | French National Agency for Research on AIDS and Viral Hepatitis | 2004-06-01 |
| Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C (NCT00154869) | National Taiwan University Hospital | 2004-06-01 |
| Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) (NCT00081770) | Merck Sharp & Dohme LLC | 2004-03-01 |
| A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment (NCT02864199) | Hoffmann-La Roche | 2004-02-01 |
| Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC). (NCT00087607) | Hoffmann-La Roche | 2004-01-01 |
| A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC). (NCT00077649) | Hoffmann-La Roche | 2004-01-01 |
| ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. (NCT00077636) | Hoffmann-La Roche | 2003-12-01 |
| IdB 1016 Treatment for Hepatitis C Disease (NCT00055445) | National Center for Complementary and Integrative Health (NCCIH) | 2003-11-01 |
| Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C (NCT00122616) | French National Agency for Research on AIDS and Viral Hepatitis | 2003-11-01 |
| A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program. (NCT00087594) | Hoffmann-La Roche | 2003-11-01 |
| REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy (NCT00087646) | Hoffmann-La Roche | 2003-09-01 |
| A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials (NCT01853254) | Hoffmann-La Roche | 2003-09-01 |
| Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) (NCT00302081) | Merck Sharp & Dohme LLC | 2003-08-01 |
| Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C (NCT00948220) | University of Ulm | 2003-07-01 |
| A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C. (NCT00475072) | Hoffmann-La Roche | 2003-06-01 |
| Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs (NCT00062816) | Ionis Pharmaceuticals, Inc. | 2003-06-01 |
| A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) (NCT02641379) | Hoffmann-La Roche | 2003-05-01 |
| A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3 (NCT01258101) | Hoffmann-La Roche | 2003-05-01 |
| Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED) (NCT00811967) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Multidisciplinary Support Program in Chronic Hepatitis C (NCT01850745) | Parc de Salut Mar | 2003-01-01 |
| A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin (NCT00087568) | Hoffmann-La Roche | 2003-01-01 |
| A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C (NCT00940420) | Hoffmann-La Roche | 2002-10-01 |
| Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C (NCT02226939) | Boehringer Ingelheim | 2002-09-01 |
| Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) (NCT00127777) | University Hospital, Saarland | 2002-07-01 |
| A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C (NCT00922779) | Hoffmann-La Roche | 2002-06-01 |
| PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) (NCT00039871) | Merck Sharp & Dohme LLC | 2002-05-01 |
| Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected Patients (NCT00221650) | University Hospital, Bordeaux | 2002-04-01 |
| Efficacy and Safety of Pentoxyphilline and Tocopherol on the Fibrosis in Patients With Chronic Hepatitis C (NCT00119119) | French National Agency for Research on AIDS and Viral Hepatitis | 2002-02-01 |
| Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection (NCT02226952) | Boehringer Ingelheim | 2001-11-01 |
| Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients (NCT00221624) | University Hospital, Bordeaux | 2001-11-01 |
| ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections (NCT00035945) | Ionis Pharmaceuticals, Inc. | 2001-10-01 |
| A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 (NCT00869661) | Hoffmann-La Roche | 2001-02-01 |
| Evaluating Silymarin for Chronic Hepatitis C (NCT00030030) | National Center for Complementary and Integrative Health (NCCIH) | 2000-07-01 |